Please Note - Streaming News is only available to subscribers to the Active Level and above
RNS News Service
I confirm that I am accessing this story in my capacity as a private investor and NOT for professional purposes.
Form 38.5(b) - Willis Towers Watson PLC
RNS
RNS Number : 7860D
Goldman Sachs & Co. LLC
30 October 2020
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader
GOLDMAN SACHS & CO. LLC
Company dealt in
WILLIS TOWERS WATSON PLC
Class of relevant security to which the dealings being disclosed relate (Note1)
USD 0.000304635 ordinary shares
Date of dealing
29 October 2020
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
Long
Short
Number
(%)
Number
(%)
(1) Relevant securities
520,909.542
(0.40)
302,219.542
(0.23)
(2) Derivatives (other than options)
50,872
(0.03)
373,212
(0.28)
(3) Options and agreements to purchase/sell
0
(0.00)
0
(0.00)
Total
571,781.542
(0.44)
675,431.542
(0.52)
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
Class of relevant security:
Long
Short
Number
(%)
Number
(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale
Number of relevant securities
Price per unit (Note 4)
Purchase
1
186.2500 USD
Purchase
95
186.2500 USD
Purchase
780
186.2500 USD
Purchase
17
186.2500 USD
Purchase
347
186.2500 USD
Purchase
3
186.2500 USD
Purchase
93
186.2500 USD
Purchase
4
186.2500 USD
Purchase
950
186.2500 USD
Purchase
1,694
186.2500 USD
Purchase
657
186.2500 USD
Purchase
100
192.6300 USD
Purchase
93
192.8200 USD
Sale
230
186.2500 USD
Sale
315
186.2500 USD
Sale
24
186.2500 USD
Sale
1,452
186.2500 USD
Sale
10
190.4200 USD
Sale
25
190.4250 USD
Sale
31
190.6400 USD
Sale
25
191.0100 USD
Sale
25
191.1100 USD
Sale
1
191.3000 USD
Sale
24
191.3400 USD
Sale
10
191.5000 USD
Sale
15
191.5000 USD
Sale
51
191.6500 USD
Sale
26
191.8500 USD
Sale
25
191.8800 USD
Sale
25
191.9200 USD
Sale
19
191.9200 USD
Sale
25
191.9400 USD
Sale
6
191.9400 USD
Sale
25
191.9400 USD
Sale
25
191.9450 USD
Sale
25
191.9600 USD
Sale
25
191.9600 USD
Sale
25
191.9900 USD
Sale
25
192.0400 USD
Sale
9
192.0700 USD
Sale
16
192.0750 USD
Sale
25
192.2550 USD
Sale
25
192.9200 USD
Sale
20
192.9200 USD
Sale
7
192.9200 USD
Sale
34
192.9200 USD
Sale
5
192.9200 USD
Sale
1
192.9200 USD
Sale
180
192.9200 USD
Sale
100
192.9300 USD
Sale
100
192.9800 USD
Sale
11
193.1400 USD
Sale
100
193.1700 USD
Sale
75
193.1900 USD
Sale
100
193.1900 USD
Sale
100
193.1900 USD
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD
Nature of transaction (Note 5)
Number of relevant securities (Note 6)
Price per unit (Note 4)
CFD
Reducing a long position
347
186.2500 USD
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name,e.g. call option
Writing, selling, purchasing, varying etc.
Number of securities to which the option relates (Note 7)
Exercise price
Type, e.g. American, European etc.
Expiry date
Option money paid/received per unit (Note 4)
(ii) Exercising
Product name,e.g. call option
Number of securities
Exercise price per unit (Note 4)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Nature of transaction (Note 7)
Details
Price per unit (if applicable) (Note 4)
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
NONE
Is a Supplemental Form 8 attached? (Note 9) YES
Date of disclosure
30 October 2020
Contact name
Kashif Rafiq and Papa Lette
Telephone number
+44(20) 7051 0547 / +44(20) 7774 7442
Name of offeree/offeror with which connected
WILLIS TOWERS WATSON PLC
Nature of connection (Note 9)
Advisor to Offeree
SUPPLEMENTAL FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
OPEN POSITIONS (Note 1)
Product name,e.g. call option
Written or purchased
Number of relevant securities to which the option or derivative relates
Exercise price (Note 2)
Type, e.g. American, European etc.
Expiry date
Swap
Sold
185
0.0000
N/A
23/09/2021
Swap
Sold
273
0.0000
N/A
04/01/2021
Swap
Sold
43,330
0.0000
N/A
14/04/2021
Swap
Sold
69,482
0.0000
N/A
14/04/2021
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rules 8 and 38.5 of the Rules. If in doubt, consult the Panel.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.